Aligos Therapeutics (ALGS) Research & Development (2019 - 2026)

Aligos Therapeutics has reported Research & Development for 8 years, with the latest figure at $23.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 61.03% year-over-year to $23.4 million; the trailing twelve-month figure through Mar 2026 stood at $78.3 million (up 14.47% YoY), and the FY2025 full-year result was $69.5 million, down 1.16% from the prior year.
• Research & Development for Q1 2026 stood at $23.4 million, up from $17.0 million in the prior quarter.
• The five-year high for Research & Development was $31.7 million in Q1 2022, with the low at $14.0 million in Q2 2025.
• Historically, Research & Development has averaged $18.9 million across 5 years, with a median of $17.0 million in 2025.
• Annual changes were most pronounced in 2023 — Research & Development plunged 42.75% — and 2026, when it jumped 61.03%.
• Aligos Therapeutics' Research & Development stood at $19.1 million in 2022, then climbed by 16.53% to $22.3 million in 2023, then declined by 27.97% to $16.0 million in 2024, then grew by 6.28% to $17.0 million in 2025, then jumped by 37.06% to $23.4 million in 2026.
• The last three Research & Development figures came in at $23.4 million (Q1 2026), $17.0 million (Q4 2025), and $23.9 million (Q3 2025), per Business Quant data.